TuHURA Biosciences And Kintara Therapeutics Announce Phase 1b Trial Of IFx-2.0 In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma And Cutaneous Squamous Cell Carcinoma Results
Portfolio Pulse from Benzinga Newsdesk
TuHURA Biosciences and Kintara Therapeutics announced positive Phase 1b trial results for IFx-2.0 in treating checkpoint inhibitor-resistant advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma. The trial showed that IFx-2.0 was safe and well-tolerated, with 80% of ICI naïve patients achieving a durable response.
June 03, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kintara Therapeutics announced positive Phase 1b trial results for IFx-2.0, showing safety and efficacy in treating advanced MCC and CSCC. This could boost investor confidence and stock price.
The positive trial results for IFx-2.0, showing both safety and efficacy, are likely to boost investor confidence in Kintara Therapeutics. This could lead to a short-term increase in the stock price as the market reacts to the promising data.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 80